DBV Technologies S.A. (DBVT)
Health Care · Biological Products, (No Diagnostic Substances)
DBVT is listed on Nasdaq, where its shares have traded since October 22, 2014. It represents shares of DBV Technologies S.A.. SentiSense covers it in the Health Care sector, and its Standard Industrial Classification is Biological Products, (No Diagnostic Substances).
About DBV Technologies S.A.
DBV Technologies SA is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. The therapeutic approach is based on epicutaneous immunotherapy or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin, an epicutaneous patch (i.e., a skin patch). Its main product candidate under development is Viaskin Peanut for the treatment of peanut-allergic patients. In addition, the company also has earlier-stage food allergy programs, including Viaskin Milk and Eosinophilic Esophagitis, or EoE.
Latest reported results
DBV Technologies S.A. reported revenue of $0.00 for Q3 FY2026.
Institutional ownership
In 13F filings for the quarter ended June 30, 2026, 78 institutions reported holding DBVT, with 21.5 million shares worth $345.7 million in aggregate. The largest reported holders were Mpm Bioimpact, Siren and Vivo Capital. Of the 5 largest reported holders, 1 added shares, 2 reduced their positions and 2 held their positions unchanged during the quarter.
More on DBVT
- DBVT sentiment: whether news and social coverage of DBV Technologies S.A. leans bullish or bearish, and the stories driving it.
- DBVT ownership: all 78 reporting institutions, plus insider and congressional trades.
- DBVT financials: revenue, net income, operating margin and free cash flow through Q3 FY2026.
SentiSense also tracks daily options readings for DBV Technologies S.A.: IV rank, put/call percentile, 25-delta skew and open-interest walls.
Frequently asked questions
What does DBV Technologies S.A. do?
DBV Technologies SA is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin.
What sector is DBVT in?
SentiSense classifies DBV Technologies S.A. in the Health Care sector, and its Standard Industrial Classification is Biological Products, (No Diagnostic Substances).
Where does DBVT stock trade?
DBVT is listed on Nasdaq, where its shares have traded since October 22, 2014. It represents shares of DBV Technologies S.A..
Who is the CEO of DBV Technologies S.A.?
Daniel Tassé is the chief executive officer of DBV Technologies S.A..